456 related articles for article (PubMed ID: 21859834)
21. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
22. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Grisham RN; Iyer G; Garg K; Delair D; Hyman DM; Zhou Q; Iasonos A; Berger MF; Dao F; Spriggs DR; Levine DA; Aghajanian C; Solit DB
Cancer; 2013 Feb; 119(3):548-554. PubMed ID: 22930283
[TBL] [Abstract][Full Text] [Related]
23. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
24. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
25. BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.
Oikonomou E; Makrodouli E; Evagelidou M; Joyce T; Probert L; Pintzas A
Neoplasia; 2009 Nov; 11(11):1116-31. PubMed ID: 19881948
[TBL] [Abstract][Full Text] [Related]
26. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.
Faddaoui A; Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Ghani K; Bachvarov D
Cell Cycle; 2017 Apr; 16(7):693-706. PubMed ID: 28278050
[TBL] [Abstract][Full Text] [Related]
27. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.
Pinciroli P; Alberti C; Sensi M; Canevari S; Tomassetti A
BMC Genomics; 2013 Jul; 14():508. PubMed ID: 23889749
[TBL] [Abstract][Full Text] [Related]
28. MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer.
Zhang Y; Zhao FJ; Chen LL; Wang LQ; Nephew KP; Wu YL; Zhang S
Oncotarget; 2014 Dec; 5(23):12291-303. PubMed ID: 25460499
[TBL] [Abstract][Full Text] [Related]
29. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
Wang YS; Ma LN; Sun JX; Liu N; Wang H
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
[TBL] [Abstract][Full Text] [Related]
31. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
32. MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4.
Lin J; Zhang L; Huang H; Huang Y; Huang L; Wang J; Huang S; He L; Zhou Y; Jia W; Yun J; Luo R; Zheng M
Oncotarget; 2015 Sep; 6(27):23793-806. PubMed ID: 26204489
[TBL] [Abstract][Full Text] [Related]
33. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
35. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
[TBL] [Abstract][Full Text] [Related]
36. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.
Hsu KF; Shen MR; Huang YF; Cheng YM; Lin SH; Chow NH; Cheng SW; Chou CY; Ho CL
Br J Cancer; 2015 Jul; 113(3):414-24. PubMed ID: 26158423
[TBL] [Abstract][Full Text] [Related]
38. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
39. EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy.
Kataoka F; Tsuda H; Arao T; Nishimura S; Tanaka H; Nomura H; Chiyoda T; Hirasawa A; Akahane T; Nishio H; Nishio K; Aoki D
Genes Chromosomes Cancer; 2012 Mar; 51(3):300-12. PubMed ID: 22095904
[TBL] [Abstract][Full Text] [Related]
40. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context.
Monticone M; Biollo E; Maffei M; Donadini A; Romeo F; Storlazzi CT; Giaretti W; Castagnola P
Mol Cancer; 2008 Dec; 7():92. PubMed ID: 19087308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
